Volume 187, Issue 6, Pages (June 2012)

Slides:

Advertisements

Similar presentations

Randomized Trial of Percutaneous Tibial Nerve Stimulation Versus Sham Efficacy in the Treatment of Overactive Bladder Syndrome: Results From the SUmiT.

Advertisements

European Urology Focus

Volume 63, Issue 1, Pages (January 2013)

Volume 186, Issue 2, Pages (August 2011)

592 PATIENT COMPLIANCE AND OUTCOMES IN BOWEL AND BLADDER DYSFUNCTION TREATED WITH PELVIC FLOOR PHYSICAL THERAPY Zachary Liss, Bryan Roelof, Theodore.

Volume 62, Issue 3, Pages (September 2012)

Volume 180, Issue 3, Pages (September 2008)

Volume 164, Issue 6, Pages (December 2000)

Volume 155, Issue 3, Pages (March 1996)

Volume 165, Issue 5, Pages (May 2001)

Volume 164, Issue 6, Pages (December 2000)

MP60-03 PROSTATE CANCER IN THE ELDERLY

Volume 70, Issue 3, Pages (September 2016)

Volume 59, Issue 2, Pages (February 2011)

Volume 195, Issue 4, Pages e13-e14 (April 2016)

Volume 68, Issue 6, Pages (December 2015)

Volume 195, Issue 5, Pages (May 2016)

2327 PROSTATE CANCER STAGE, GRADE AND POSITIVE MARGIN RATE IN MEN WITH PSA ≥ 1 ng/ml UNDERGOING RADICAL PROSTATECTOMY: POPULATION DATA ANALYSIS Sergey.

Volume 191, Issue 6, Pages (June 2014)

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 66, Issue 4, Pages (October 2014)

Volume 199, Issue 1, Pages (January 2018)

Volume 199, Issue 4, Pages e143-e144 (April 2018)

Volume 186, Issue 5, Pages (November 2011)

Volume 199, Issue 6, Pages (June 2018)

Volume 52, Issue 3, Pages (September 2007)

Oncocytoma of the Kidney

Volume 52, Issue 4, Pages (October 2007)

Volume 183, Issue 3, Pages (March 2010)

Volume 189, Issue 1, Pages (January 2013)

Volume 59, Issue 2, Pages (February 2011)

Volume 189, Issue 1, Pages S45-S50 (January 2013)

Volume 199, Issue 1, Pages (January 2018)

Pseudohyperplastic Adenocarcinoma of the Prostate

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 184, Issue 4, Pages (October 2010)

Volume 185, Issue 6, Pages (June 2011)

Volume 199, Issue 4, Pages (April 2018)

Volume 185, Issue 2, Pages (February 2011)

Gastrointestinal Endoscopy

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

The Impact of Race on the Prognosis of Preclinical Diastolic Dysfunction: A Large Multiracial Urban Population Study Jian Shan, MD, Lili Zhang, MD, MSc,

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 66, Issue 2, Pages (August 2014)

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial Marko Kalliomäki, MD, PhD,

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

Three Versus 4 Daily Exchanges and Residual Kidney Function Decline in Incident CAPD Patients: A Randomized Controlled Trial Hao Yan, MD, Wei Fang, MD,

Volume 55, Issue 6, Pages (June 2009)

Predictors of the Risk of Mortality in Neurofibromatosis 2

Survival of Women With Cancer in Palliative Care: Use of the Palliative Prognostic Score in a Population of Brazilian Women Cláudia Naylor, MD, Lúcia.

Long-Term Hormonal Therapy: Who Would Benefit?

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios

Axel Heidenreich European Urology Supplements

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

Highlighting Unmet Needs: Real Patients, Difficult Choices

Clinical Relevance of Our Multimodality Prognostic Score

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

American Journal of Kidney Diseases

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Surgical outcomes after cardiac surgery in liver transplant recipients

Axel Heidenreich European Urology Supplements

A Randomized Controlled Trial of Coiled Versus Straight Swan-Neck Tenckhoff Catheters in Peritoneal Dialysis Patients David W. Johnson, PhD, Jennifer.

Volume 69, Issue 4, Pages (April 2016)

Presentation transcript:

Volume 187, Issue 6, Pages 2074-2081 (June 2012) The FinnProstate Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Arto J. Salonen, Kimmo Taari, Martti Ala-Opas, Jouko Viitanen, Seppo Lundstedt, Teuvo L.J. Tammela The Journal of Urology Volume 187, Issue 6, Pages 2074-2081 (June 2012) DOI: 10.1016/j.juro.2012.01.122 Copyright © 2012 American Urological Association Education and Research, Inc. Terms and Conditions

Figure 1 Kaplan-Meier curves for PFS, OS, PCS and TF survival in intermittent and continuous treatment arms. Cum, cumulative. The Journal of Urology 2012 187, 2074-2081DOI: (10.1016/j.juro.2012.01.122) Copyright © 2012 American Urological Association Education and Research, Inc. Terms and Conditions

Figure 2 Kaplan-Meier curves for PFS, OS, PCS and TF survival by PSA at randomization in trial population. PSA less than 1.0 (206), 1.0 to 4.0 (229), greater than 4.0 ng/ml (118) with p values for log rank tests. Of 553 patients 1 refused intermittent trial therapy. Cum, cumulative. The Journal of Urology 2012 187, 2074-2081DOI: (10.1016/j.juro.2012.01.122) Copyright © 2012 American Urological Association Education and Research, Inc. Terms and Conditions

Figure 3 Kaplan-Meier curves for PFS, OS, PCS and TF survival by differentiation grade of Gleason scores 6–7 (205) and 8–10 (286). Log rank p <0.001. Cum, cumulative. The Journal of Urology 2012 187, 2074-2081DOI: (10.1016/j.juro.2012.01.122) Copyright © 2012 American Urological Association Education and Research, Inc. Terms and Conditions